Skip to main content
Erschienen in: Supportive Care in Cancer 11/2005

01.11.2005 | Short Communication

Do cancer patients benefit from short-term contact with a general practitioner following cancer treatment? A randomised, controlled study

verfasst von: Knut Holtedahl, Jan Norum, Tor Anvik, Elin Richardsen

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

To investigate whether increased contact with the patient’s general practitioner (GP) soon after cancer treatment can increase patient quality of life (QoL) and satisfaction with follow-up.

Patients and methods

A randomised controlled study with 91 patients from one Norwegian municipality. The intervention group got a 30-min invited consultation with the patient’s GP and an invitation to further GP follow-up. Quality of life and patient satisfaction with diagnosis, treatment and overall care were measured with validated instruments.

Main results

Relatives’ satisfaction with care increased over 6 months in the intervention group (P=0.018), but otherwise, there was no difference between the intervention and control groups concerning QoL, satisfaction with care or number of consultations. Patient satisfaction with care showed a tendency to increase when treatment intent was curative. Some functional QoL measures and satisfaction tended to increase during the first 6 months after treatment. Free text comments suggested that some patients appreciated the contact with their GP.

Conclusion

Some cancer patients benefit from follow-up by their GP. The way to perform this kind of follow-up in primary care, and who these cancer patients are, should be further studied. Short follow-up time and an urban setting may have contributed to the lack of group differences in our study, but patients treated for cancer may have limited need for follow-up as long as they feel well and the situation remains stable.
Literatur
1.
Zurück zum Zitat Aaraas I, Førde OJ, Kristiansen IS, Melbye H (1998) Do general practitoner hospitals reduce the utilisation of general hospital beds? Evidence from Finnmark county in north Norway. J Epidemiol Community Health 52:243–246 Aaraas I, Førde OJ, Kristiansen IS, Melbye H (1998) Do general practitoner hospitals reduce the utilisation of general hospital beds? Evidence from Finnmark county in north Norway. J Epidemiol Community Health 52:243–246
2.
Zurück zum Zitat Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez J et al. for the European Organisation for Research and Treatment of Cancer Study Group on Quality of Life et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376 Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez J et al. for the European Organisation for Research and Treatment of Cancer Study Group on Quality of Life et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
3.
Zurück zum Zitat Baker R, Preston C, Cheater F, Hearnshaw H (1999) Measuring patients’ attitudes to care across the primary/secondary interface: the development of the patient career diary. Qual Health Care 8:154–160 Baker R, Preston C, Cheater F, Hearnshaw H (1999) Measuring patients’ attitudes to care across the primary/secondary interface: the development of the patient career diary. Qual Health Care 8:154–160
4.
Zurück zum Zitat Cheater FM, Preston C, Wynn A, Hearnshaw H, Baker R (1999) Patients’ views of cancer services: development of a questionnaire for accreditation. Eur J Oncol Nurs 3:72–82 Cheater FM, Preston C, Wynn A, Hearnshaw H, Baker R (1999) Patients’ views of cancer services: development of a questionnaire for accreditation. Eur J Oncol Nurs 3:72–82
5.
Zurück zum Zitat Grunfeld E, Fitzpatrick R, Mant D, Yudkin P, Adewuyi-Dalton R, Stewart J, Cole D, Vessey M (1999) Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Br J Gen Pract 49:705–710 Grunfeld E, Fitzpatrick R, Mant D, Yudkin P, Adewuyi-Dalton R, Stewart J, Cole D, Vessey M (1999) Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Br J Gen Pract 49:705–710
6.
Zurück zum Zitat Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, Fitzpatrick R, Vessey M (1996) Routine follow-up of breast cancer in primary care: randomised trial. BMJ 313:665–669 Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, Fitzpatrick R, Vessey M (1996) Routine follow-up of breast cancer in primary care: randomised trial. BMJ 313:665–669
7.
Zurück zum Zitat Kattlove H, Winn RJ (2003) Ongoing care of patients after primary treatment for their cancer. CA Cancer J Clin 53:172–196 Kattlove H, Winn RJ (2003) Ongoing care of patients after primary treatment for their cancer. CA Cancer J Clin 53:172–196
8.
Zurück zum Zitat Nielsen JD, Palshof T, Mainz J, Jensen AB, Olesen F (2003) Randomised controlled trial of a shared care programme for newly referred cancer patients: bridging the gap between general practice and hospital. Qual Saf Health Care 12:263–272 Nielsen JD, Palshof T, Mainz J, Jensen AB, Olesen F (2003) Randomised controlled trial of a shared care programme for newly referred cancer patients: bridging the gap between general practice and hospital. Qual Saf Health Care 12:263–272
9.
Zurück zum Zitat Norman A, Sisler J, Hack T, Harlos M (2001) Family physicians and cancer care. Palliative care patients’ perspectives. Can Fam Physician 47:2009–2016 Norman A, Sisler J, Hack T, Harlos M (2001) Family physicians and cancer care. Palliative care patients’ perspectives. Can Fam Physician 47:2009–2016
10.
Zurück zum Zitat Ringdal G, Ringdal K (1993) Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogenous diagnoses. Qual Life Res 2:129–140 Ringdal G, Ringdal K (1993) Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogenous diagnoses. Qual Life Res 2:129–140
11.
Zurück zum Zitat Smith SM, Campbell NC (2004) Provision of oncology services in remote rural areas: a Scottish perspective. Eur J Cancer Care 13:185–192 Smith SM, Campbell NC (2004) Provision of oncology services in remote rural areas: a Scottish perspective. Eur J Cancer Care 13:185–192
12.
Zurück zum Zitat Tattersall MHN, Thomas H (1999) Recent advances: oncology. BMJ 318:445–448 Tattersall MHN, Thomas H (1999) Recent advances: oncology. BMJ 318:445–448
13.
Zurück zum Zitat Zitzelsberger L, Grunfeld E, Graham ID (2004) Family physicians’ perspectives on practice guidelines related to cancer control. BMC Fam Pract 5:25 Zitzelsberger L, Grunfeld E, Graham ID (2004) Family physicians’ perspectives on practice guidelines related to cancer control. BMC Fam Pract 5:25
Metadaten
Titel
Do cancer patients benefit from short-term contact with a general practitioner following cancer treatment? A randomised, controlled study
verfasst von
Knut Holtedahl
Jan Norum
Tor Anvik
Elin Richardsen
Publikationsdatum
01.11.2005
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0869-5

Weitere Artikel der Ausgabe 11/2005

Supportive Care in Cancer 11/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.